Health Trials

Gliomas Harboring IDH1 and/or IDH2 Mutations

2

Review clinical trials related to Gliomas Harboring IDH1 and/or IDH2 Mutations. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.

Participants needed: 500
Trial details
Biological sex: AllType: ObservationalSponsor: Xiangya Hospital of Central South UniversityUpdated: May 27, 2026Locations: 1Duration: 3 Years
Eligibility criteria

Patients with diffuse gliomas were pathologically and molecularly diagnosed. [+2]

The tumor is not located in the intracranial midline. [+1]

Read more
Status: Recruiting

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations

Participants needed: 52
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: HutchmedUpdated: Aug 1, 2025Locations: 1
Eligibility criteria

Fully informed about the study and voluntarily sign the informed consent form (I... [+6]

Previous treatment with IDH inhibitors. [+8]

Read more